Debt-to-equity of MoonLake Immunotherapeutics from 30 Sep 2021 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
MoonLake Immunotherapeutics quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 31 Dec 2025.
  • MoonLake Immunotherapeutics Debt-to-equity for the quarter ending 31 Dec 2025 was 33%, a 787% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

MoonLake Immunotherapeutics Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 33% +29% +787% 31 Dec 2025
Q3 2025 23% +20% +665% 30 Sep 2025
Q2 2025 15% +12% +478% 30 Jun 2025
Q1 2025 8.6% +6.4% +293% 31 Mar 2025
Q4 2024 3.7% +1% +38% 31 Dec 2024
Q3 2024 3% -0.32% -9.5% 30 Sep 2024
Q2 2024 2.5% -2.1% -45% 30 Jun 2024
Q1 2024 2.2% -10% -82% 31 Mar 2024
Q4 2023 2.7% -114% -98% 31 Dec 2023
Q3 2023 3.4% -178% -98% 30 Sep 2023
Q2 2023 4.6% -329% -99% 30 Jun 2023
Q1 2023 12% -1834% -99% 31 Mar 2023
Q4 2022 117% +370% 31 Dec 2022
Q3 2022 181% +554% 30 Sep 2022
Q2 2022 333% 30 Jun 2022
Q1 2022 1846% 31 Mar 2022
Q4 2021 -253% 31 Dec 2021
Q3 2021 -373% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.